OTCMKTS:EVTCY - Evotec Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $45.00 0.00 (0.00 %) (As of 01/18/2019 04:00 PM ET)Previous Close$45.00Today's Range$45.00 - $45.0052-Week Range$29.4750 - $52.50Volume3 shsAverage Volume883 shsMarket Capitalization$3.30 billionP/E Ratio125.00Dividend YieldN/ABeta0.97 ProfileDiscussionAnalyst RatingsChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services. The company is also involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. It has a drug discovery and development partnerships with Celgene Corporation; Novo Nordisk A/S; Sanofi; Almirall, S.A.; Ferring Pharmaceuticals; Centogene AG; Immuneering Corporation; and LEO Pharma A/S. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Receive EVTCY News and Ratings via Email Sign-up to receive the latest news and ratings for EVTCY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:EVTCY Previous Symbol CUSIPN/A Webwww.evotec.com Phone49-4056-0810Debt Debt-to-Equity Ratio0.07 Current Ratio0.93 Quick Ratio0.90Price-To-Earnings Trailing P/E Ratio125.00 Forward P/E Ratio45.00 P/E GrowthN/A Sales & Book Value Annual Sales$291.02 million Price / Sales11.34 Cash Flow$0.7088 per share Price / Cash Flow63.49 Book Value$5.11 per share Price / Book8.81Profitability EPS (Most Recent Fiscal Year)$0.36 Net Income$27.41 million Net Margins17.48% Return on Equity14.85% Return on Assets7.51%Miscellaneous Employees2,178 Outstanding Shares73,350,000Market Cap$3.30 billion OptionableNot Optionable Evotec (OTCMKTS:EVTCY) Frequently Asked Questions What is Evotec's stock symbol? Evotec trades on the OTCMKTS under the ticker symbol "EVTCY." How were Evotec's earnings last quarter? Evotec AG (OTCMKTS:EVTCY) posted its quarterly earnings data on Tuesday, November, 13th. The company reported $0.34 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.14 by $0.20. The business earned $111.94 million during the quarter. Evotec had a net margin of 17.48% and a return on equity of 14.85%. View Evotec's Earnings History. When is Evotec's next earnings date? Evotec is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Evotec. What is the consensus analysts' recommendation for Evotec? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evotec. Has Evotec been receiving favorable news coverage? News articles about EVTCY stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evotec earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next few days. Who are some of Evotec's key competitors? Some companies that are related to Evotec include Merck KGaA (MKGAF), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Amarin (AMRN) and GALAPAGOS NV/S (GLPG). Who are Evotec's key executives? Evotec's management team includes the folowing people: Dr. Werner Lanthaler, CEO & Member of Management Board (Age 51)Mr. Enno Spillner, CFO & Member of Management Board (Age 49)Dr. Mario Polywka, COO & Member of Management Board (Age 56)Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 55)Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting How do I buy shares of Evotec? Shares of EVTCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Evotec's stock price today? One share of EVTCY stock can currently be purchased for approximately $45.00. How big of a company is Evotec? Evotec has a market capitalization of $3.30 billion and generates $291.02 million in revenue each year. The company earns $27.41 million in net income (profit) each year or $0.36 on an earnings per share basis. Evotec employs 2,178 workers across the globe. What is Evotec's official website? The official website for Evotec is http://www.evotec.com. How can I contact Evotec? Evotec's mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The company can be reached via phone at 49-4056-0810 or via email at [email protected] MarketBeat Community Rating for Evotec (OTCMKTS EVTCY)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 127 (Vote Outperform)Underperform Votes: 108 (Vote Underperform)Total Votes: 235MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe EVTCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVTCY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: Is a Roth IRA right for you?